Mary Elizabeth Strek to Time Factors
This is a "connection" page, showing publications Mary Elizabeth Strek has written about Time Factors.
Connection Strength
0.290
-
The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry. Respir Res. 2024 Jun 21; 25(1):255.
Score: 0.126
-
Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J. 2016 06; 47(6):1767-75.
Score: 0.071
-
High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease. Sci Rep. 2021 11 24; 11(1):22821.
Score: 0.026
-
Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30; 22(1):257.
Score: 0.026
-
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
Score: 0.025
-
Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18; 31(1):46-54.
Score: 0.016